Entrada Therapeutics, Inc.

NasdaqGM TRDA

Entrada Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 98.39%

Entrada Therapeutics, Inc. Gross Profit Margin is 98.39% for the Trailing 12 Months (TTM) ending September 30, 2024, a 1.37% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Entrada Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 97.06%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGM: TRDA

Entrada Therapeutics, Inc.

CEO	Mr. Dipal Doshi
IPO Date	Oct. 29, 2021
Location	United States
Headquarters	6 Tide Street
Employees	177
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years